MedPal AI (LSE:MPAL) reported record activity at its pharmacy subsidiary, MedPal Limited, after dispensing 41,600 prescription items in March 2026—an increase of 27.5% compared with the previous month. Since launch, the platform has now processed approximately 200,000 prescription items in total.
Based on March’s performance, the pharmacy business is now operating at an annualised turnover exceeding £5 million. The unit is also delivering gross margins of more than 34%, supported by its automated and technology-driven dispensing infrastructure.
The company noted that growth has been driven by rising demand across both its NHS Distance Selling Pharmacy services and private prescriptions fulfilled through MedPal.clinic. Interest in GLP-1 weight-loss medications has also contributed to increased prescription volumes.
Management added that the company’s automated pharmacy infrastructure still has significant unused capacity. This provides scope to scale dispensing volumes further without a proportional rise in operating costs, positioning MedPal AI to benefit from growth in the UK’s digital pharmacy and obesity treatment markets.
More about MedPal AI Plc
MedPal AI plc is a UK-based digital health company that has developed the MedPal Health OS, a vertically integrated platform combining AI-driven wellness tools, clinical services and automated pharmacy fulfilment. Its core mobile application connects with more than 100 wearable devices and health apps, delivering personalised lifestyle insights while serving as a gateway to the company’s medical and pharmacy services. These include a 24/7 AI-powered robotic dispensing facility capable of serving NHS and private prescription customers across the UK.
Leave a Reply